A Phase 3 interventional study of dabigatran etexilate in Venous Thromboembolism and Secondary Prevention, sponsored by Boehringer Ingelheim. Completed at 62 sites in 22 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-06-04.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.
Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 13th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is below the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 148 across the 17 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 6 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
17 studies in Venous Thromboembolism by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 15 finished, 13 (87%) have results posted.
Among the 17 studies in Venous Thromboembolism by Boehringer Ingelheim, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2014, is one of 4 in phase 3, and was the 13th registered.
Boehringer Ingelheim’s Venous Thromboembolism studies by the year they started, since 2000.
1 of the studies testing dabigatran in Venous Thromboembolism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing dabigatran in Venous Thromboembolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 17 in Venous Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: dabigatran etexilate
Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months
The event-free probability of first recurrence of VTE were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience recurrent VTE at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-VTE related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
Time frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period
Event-free Probability of Major or Minor (Including Clinically Relevant Non-major (CRNM)) Bleeding Events at 6 and 12 Months
The event-free probability of major or minor (including CRNM) bleeding event were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience major or minor (including CRNM) bleeding event at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-bleeding related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
Time frame: At month 6 (Week 26) and month 12 (Week 52) of on treatment period
Event-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months
The event-free probability of mortality overall and related to thrombotic or thromboembolic events were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience mortality overall and related to thrombotic or thromboembolic events at the time of analysis, dropped out from the trial early, were lost to follow-up, were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
Time frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period
Event-free Probability of Occurrence of Post-thrombotic Syndrome (PTS) at 6 and 12 Months
The event-free probability of PTS were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience PTS at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-PTS related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
Time frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period
Percentage of Participants With Dabigatran Etexilate (DE) Dose Adjustments During on Treatment Period
Percentage of participants with dabigatran etexilate dose adjustments during on treatment period. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
Time frame: From first DE administration to 3 days of residual effect period after last DE administration, up to 52 weeks+ 3 days
Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Time frame: At Visit 3 (day 4 after first dose of trial medication)
Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Time frame: Pharmacodynamics (PD) samples were collected from first dose of trial medication at day 1 and day 4, 22, 43, 85, 127, 183, 239 and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.
Central Measurement of Ecarin Clotting Time (ECT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Time frame: At Visit 3 (day 4 after first dose of trial medication)
Central Measurement of Ecarin Clotting Time (ECT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Time frame: Pharmacodynamics (PD) samples were collected from first dose of trial medication at day 1 and day 4, 22, 43, 85, 127, 183, 239 and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.
Central Measurement of Diluted Thrombin Time (dTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Time frame: At Visit 3 (day 4 after first dose of trial medication)
Central Measurement of Diluted Thrombin Time (dTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Time frame: dTT values were collected at day 4, 22, 43, 85, 127, 183, 239, and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.
This open label, single arm prospective cohort study was designed to assess the safety of dabigatran etexilate (DE) for secondary prevention of paediatric venous thromboembolism (VTE) with 12-month (365 days) treatment period followed by 28 days end of treatment follow-up. Results of participants were reported via 3 mutually exclusive age groups.
| Milestone | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Started | 9 | 43 | 161 |
| Completed | 8 | 39 | 153 |
| Not completed | 1 | 4 | 8 |
| Withdrew: Other reasons | 0 | 2 | 5 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
The event-free probability of first recurrence of VTE were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience recurrent VTE at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-VTE related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
| Probability | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| 6 months | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | 0.979 (0.937 to 0.993) |
| 12 months | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | 0.979 (0.937 to 0.993) |
The event-free probability of major or minor (including CRNM) bleeding event were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience major or minor (including CRNM) bleeding event at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-bleeding related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
| Probability | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| 6 months | 0.889 (0.433 to 0.984) | 0.894 (0.706 to 0.965) | 0.753 (0.675 to 0.815) |
| 12 months | 0.889 (0.433 to 0.984) | 0.831 (0.592 to 0.936) | 0.691 (0.603 to 0.763) |
The event-free probability of mortality overall and related to thrombotic or thromboembolic events were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience mortality overall and related to thrombotic or thromboembolic events at the time of analysis, dropped out from the trial early, were lost to follow-up, were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
| Probability | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| 6 months | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) |
| 12 months | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) |
The event-free probability of PTS were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience PTS at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-PTS related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
| Probability | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| 6 months | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | 0.979 (0.935 to 0.993) |
| 12 months | 1.000 (1.000 to 1.000) | 1.000 (1.000 to 1.000) | 0.979 (0.935 to 0.993) |
Percentage of participants with dabigatran etexilate dose adjustments during on treatment period. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.
| Percentage of participants | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Percentage of Participants With Dabigatran Etexilate (DE) Dose Adjustments During on Treatment Period | 66.7 | 39.5 | 21.1 |
| Second (s) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses) | 46.6 ± 18.1 | 57.1 ± 70.4 | 56.8 ± 64.6 |
| Second (s) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment) | 49.1 ± 26.8 | 57.3 ± 23.9 | 59.0 ± 80.8 |
| Second (s) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Central Measurement of Ecarin Clotting Time (ECT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses) | 52.7 ± 17.6 | 64.3 ± 55.7 | 69.5 ± 30.3 |
| Second (s) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Central Measurement of Ecarin Clotting Time (ECT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment) | 53.3 ± 19.4 | 66.6 ± 23.6 | 69.2 ± 28.7 |
| Second (s) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Central Measurement of Diluted Thrombin Time (dTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses) | 37.9 ± 19.5 | 40.5 ± 14.6 | 45.3 ± 17.4 |
| Second (s) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) |
|---|---|---|---|
| Central Measurement of Diluted Thrombin Time (dTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment) | 40.0 ± 24.3 | 46.0 ± 18.6 | 43.4 ± 17.7 |
Collected over From first dose until last dose of study drug + 3 days of residual effect period, up to 52 weeks + 3 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate (Treated Set) | 0/213 (0%) | 30/213 (14.1%) | 113/213 (53.1%) |
| Event | Dabigatran Etexilate (Treated Set) |
|---|---|
| PneumoniaInfections and infestations | 2/213 |
| TonsillitisInfections and infestations | 2/213 |
| Deep vein thrombosisVascular disorders | 2/213 |
| Atrial flutterCardiac disorders | 1/213 |
| Cardiac failureCardiac disorders | 1/213 |
| MyocarditisCardiac disorders | 1/213 |
| Pericardial effusionCardiac disorders | 1/213 |
| Ventricular pre-excitationCardiac disorders | 1/213 |
| Congenital anomalyCongenital, familial and genetic disorders | 1/213 |
| Abdominal pain upperGastrointestinal disorders | 1/213 |
| Event | Dabigatran Etexilate (Treated Set) |
|---|---|
| NasopharyngitisInfections and infestations | 34/213 |
| HeadacheNervous system disorders | 34/213 |
| NauseaGastrointestinal disorders | 17/213 |
| DiarrhoeaGastrointestinal disorders | 15/213 |
| DyspepsiaGastrointestinal disorders | 15/213 |
| VomitingGastrointestinal disorders | 15/213 |
| PyrexiaGeneral disorders | 15/213 |
| Upper respiratory tract infectionInfections and infestations | 14/213 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/213 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 14/213 |
The treated set (TS) included all patients who were dispensed trial medication and had taken at least 1 dose of investigational treatment, which was used to assess safety endpoints, demographics and baseline characteristics.
| Age, Continuous(Years) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) | Total |
|---|---|---|---|---|
| Mean | 0.6 ± 0.5 | 6.8 ± 3.1 | 15.1 ± 1.6 | 12.8 ± 4.6 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) | Total |
|---|---|---|---|---|
| Female | 4 | 22 | 70 | 96 |
| Male | 5 | 21 | 91 | 117 |
| Ethnicity (NIH/OMB)(Participants) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 7 | 9 |
| Not Hispanic or Latino | 9 | 41 | 153 | 203 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Dabigatran Etexilate (0 to < 2 Years) | Dabigatran Etexilate (2 to <12 Years) | Dabigatran Etexilate (12 to <18 Years) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 6 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 4 | 4 | 8 |
| White | 8 | 37 | 149 | 194 |
| More than one race | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Oct 2019, 60 months.
Results were first posted in Jun 2020, 7 months after primary completion.
Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran